Floatz logo

Dinutuximab

Relapsed Solid Tumor

Eli Lilly and Companymonoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Relapsed Solid Tumor cohort.

Asset / SponsorPhaseRating
Eloxatin
Sidnei Epelman
Phase 2CCC
Irinotecan
Eli Lilly and Company
Phase 1/2CCC
Gm-Csf
Eli Lilly and Company
Phase 1/2CCC
Abemaciclib
Eli Lilly and Company
Phase 1/2CCC
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 1/2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN PROGRAMMED DEATH-LIGAND 1) (HUMAN MONOCLONAL STI-3031 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL STI-3031 .LAMBDA.-CHAIN, DIMER
Sorrento Therapeutics, Inc.
Phase 2CC

Same molecule, other indications

Dinutuximab is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
refractory malignant neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →